tiprankstipranks
Advertisement
Advertisement

TAK Stock Latest News

Takeda’s Replagal Trial in India: Fresh Clinical Update With Rare Disease Upside
Company AnnouncementsTakeda’s Replagal Trial in India: Fresh Clinical Update With Rare Disease Upside
5h ago
TAK
Trump Trade: President warns communities against rejecting data centers
PremiumThe Fly
Trump Trade: President warns communities against rejecting data centers
2d ago
AZN
LLY
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
PremiumThe Fly
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
2d ago
TAK
PTGX
Bayer, Takeda expected to announce new pricing deals with White House, FT says
PremiumThe Fly
Bayer, Takeda expected to announce new pricing deals with White House, FT says
3d ago
AZN
LLY
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
PremiumThe Fly
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
3d ago
TAK
PTGX
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
PremiumThe FlyProtagonist announces Takeda received U.S. FDA approval for MIMRYLO
4d ago
TAK
PTGX
Takeda receives FDA approval of NDA for Mimrylo
Premium
The Fly
Takeda receives FDA approval of NDA for Mimrylo
6d ago
TAK
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
Premium
The Fly
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
6d ago
SNY
TAK
Takeda announces Japan MHLW approval for Orzeyful
PremiumThe Fly
Takeda announces Japan MHLW approval for Orzeyful
11d ago
TAK
Takeda’s Real-World CMV Study in Argentina Reaches Key Milestone
PremiumCompany Announcements
Takeda’s Real-World CMV Study in Argentina Reaches Key Milestone
13d ago
TAK
Takeda Targets China PV Market With New Rusfertide Trial
PremiumCompany Announcements
Takeda Targets China PV Market With New Rusfertide Trial
20d ago
TAK
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
PremiumRatings
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
21d ago
TAK
Takeda award from Veterans Affairs posted to SAM.gov site
PremiumThe FlyTakeda award from Veterans Affairs posted to SAM.gov site
24d ago
TAK
Takeda’s LIVTENCITY CMV Study in Japan: What Investors Should Watch
Premium
Company Announcements
Takeda’s LIVTENCITY CMV Study in Japan: What Investors Should Watch
27d ago
TAK
Takeda Targets High-Need Psoriasis Niche With New Phase 3b Zasocitinib Study
Premium
Company Announcements
Takeda Targets High-Need Psoriasis Niche With New Phase 3b Zasocitinib Study
27d ago
TAK
Takeda’s Brazil IBD Study Wraps Up, Offering Fresh Clues on Vedolizumab Performance
PremiumCompany Announcements
Takeda’s Brazil IBD Study Wraps Up, Offering Fresh Clues on Vedolizumab Performance
27d ago
TAK
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
PremiumThe Fly
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
29d ago
TAK
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
PremiumThe Fly
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
29d ago
TAK
Takeda Earnings Call: FX Tailwinds, Pipeline Firepower
PremiumCompany Announcements
Takeda Earnings Call: FX Tailwinds, Pipeline Firepower
30d ago
TAK
Takeda Advances Pediatric Pouchitis Trial, Extending Entyvio’s Long‑Term Growth Story
PremiumCompany AnnouncementsTakeda Advances Pediatric Pouchitis Trial, Extending Entyvio’s Long‑Term Growth Story
1M ago
TAK
Takeda Tracks Real World Safety of Ceprotin (TAK-662) in Rare Clotting Disorder
Premium
Company Announcements
Takeda Tracks Real World Safety of Ceprotin (TAK-662) in Rare Clotting Disorder
1M ago
TAK
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
Premium
The Fly
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
1M ago
TAK
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >